Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Bioatla Inc BCAB

Healthcare Biotechnology
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BCAB)

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

GlobeNewswire November 7, 2024

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

GlobeNewswire October 31, 2024

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire October 4, 2024

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

GlobeNewswire October 1, 2024

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

GlobeNewswire September 23, 2024

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

GlobeNewswire September 16, 2024

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

GlobeNewswire September 9, 2024

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 28, 2024

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

GlobeNewswire August 8, 2024
View More News ››

Opinion & Analysis (NDAQ:BCAB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BCAB)

BioAtla and Context Therapeutics Announce Exclusive Worldwid

News; $BCAB BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a...
whytestocks - September 23, 2024

BioAtla to Host Virtual R&D Day on Clinical Program and Pipe

NEWS: $BCAB BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 | BenzingaSAN DIEGO, June 27...
whytestocks - June 27, 2024
View more Bullboard ››

SKRR Exploration Inc.

SKRR Exploration Inc.

SKRR Exploration Inc. is a Canada-based precious and base metal explorer with properties in Saskatchewan. The Company's ...
View More »